SAN DIEGO, Calif.–(BUSINESS WIRE)–Seattle Genetics, Inc. (Nasdaq:SGEN) today highlighted data from the ECHELON-1 phase 3 clinical trial evaluating ADCETRIS (brentuximab vedotin) in combination with AVD (Adriamycin®, vinblastine and dacarbazine) in newly diagnosed stage III or IV classical Hodgkin lymphoma (HL) at the 60th American Society of Hematology (ASH) Annual Meeting and Exposition …
Tag Archives: HL
December, 2018
May, 2016
-
18 May
FDA Grants Accelerated Approval to BMS’ Opdivo for Classical Hodgkin Lymphoma
PRINCETON, N.J.–(BUSINESS WIRE)–Bristol-Myers Squibb Company (NYSE:BMY) today announced the U.S. Food and Drug Administration (FDA) has approved Opdivo®(nivolumab) for the treatment of patients with classical Hodgkin lymphoma (cHL) who have relapsed or progressed after autologous hematopoietic stem cell transplantation (auto-HSCT) and post-transplantation brentuximab vedotin.1 This accelerated approval is based on …